@FiercePharma: Popular on FiercePharmaMarketing: Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story | Follow @FiercePharma
@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. PR, ICYMI. Earnings statement (PDF) | Follow @TracyStaton
@EricPFierce: Hikma builds more heft in sterile manufacturing. Say it will take equipment out of closed Ben Venue plant. News | Follow @EricPFierce
@CarlyHFierce: Today in FiercePharmaMarketing: Doom for combo meds? PBMs dump 2-in-1 drugs; 'Name-calling' at FDA. Issue | Follow @CarlyHFierce
> Hospira's ($HSP) second-quarter profit more than doubled, easily beating out analysts' expectations. Report (sub. req.)
> Vertex ($VRTX) posted a wider Q2 loss, topping analyst forecasts. Report
> A U.S. Senate panel will take a look at price-setting for contact lenses. Report
> The European Commission (EC) has approved Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) Eliquis for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE. Release
> India's Lupin expects its domestic sales to grow 18% to 20% in fiscal 2015. Report
> Record physician demand drove a 27% increase in U.S. net Feraheme revenues for Amag Pharmaceuticals ($AMAG). Release
> GlaxoSmithKline's ($GSK) once-weekly diabetes treatment Tanzeum is now available in pharmacies in the U.S. Release
Medical Device News
@FierceMedDev: Dental implant player Nobel Biocare is the latest med tech M&A target. Story | Follow @FierceMedDev
@StacyALawrence: Large healthcare customers squeeze med tech supplier Owens & Minor. Article | Follow @StacyALawrence
@VarunSaxena2: AcelRx discusses sublingual painkiller's rejection with concerned investors. FierceDrugDelivery article | Follow @VarunSaxena2
@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce
@EmilyWFierce: Epic Sciences ropes in $PFE and $RHHBY funding to commercialize CTC tests for cancer treatment. FierceDiagnostics story | Follow @EmilyWFierce
> Kickstarter in vogue as funding mechanism for new devices. Story
> What will changes to the Sunshine Act mean for devicemakers? Item
> Coloplast adding 150 jobs in the U.K. to boost chronic care business. Article
Biotech News
@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech
@JohnCFierce: I used to make fun of $PFE's big in-licensing deals (remember Medivation and Alzheimer's?) I'm switching to out-licensing now (neratinib). | Follow @JohnCFierce
@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. More | Follow @DamianFierce
@EmilyMFierce: Ebola treatments caught in limbo. Nature piece | Follow @EmilyMFierce
> Sanofi, Regeneron prep their PCSK9 cardio contender for FDA review after PhIII sweep. Report
> Gilead bags a portfolio of HIV-neutralizing antibodies. Item
> Immuno-oncology partnering-palooza continues with Genentech, AstraZeneca deals. Article
Drug Delivery News
> Amid fears of shortage of antibiotics, DNA origami technique developed to combat E. coli, other bugs. Article
> Nanoparticles deliver agents to spur immune system into action against cancer. Story
> Developer of unique delivery technology for eye care expanding in Europe. Item
> Nature-inspired artificial cilia could help move drugs to a target. More
> AcelRx discusses sublingual painkiller's rejection with concerned investors. Article
Diagnostics News
> In Q2, diagnostics venture investment showed some signs of life. More
> Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table. Article
> Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test. Story
> Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. Article
> Mela Sciences pulls in funding to fuel reimbursement push for melanoma Dx device. Item
Pharma Marketing News
> Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs. Report
> Name-calling: The FDA needs your ideas for locking down brand monikers. More
> AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits. More
> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story
> Merck spokeswoman: Sales layoffs to hit PA-based field reps. Article
And Finally... A gene tied to negative thoughts and impulses may help researchers create a blood test predicting suicide risk. Story